The estimated Net Worth of David W Dockhorn is at least $17.3 Million dollars as of 28 December 2017. David Dockhorn owns over 72,850 units of PRA Health Sciences Inc stock worth over $12,035,549 and over the last 8 years David sold PRAH stock worth over $5,255,593.
David has made over 4 trades of the PRA Health Sciences Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently David exercised 72,850 units of PRAH stock worth $854,531 on 28 December 2017.
The largest trade David's ever made was exercising 114,084 units of PRA Health Sciences Inc stock on 5 August 2016 worth over $335,407. On average, David trades about 75,875 units every 102 days since 2016. As of 28 December 2017 David still owns at least 72,850 units of PRA Health Sciences Inc stock.
You can see the complete history of David Dockhorn stock trades at the bottom of the page.
David's mailing address filed with the SEC is C/O PRA HEALTH SCIENCES, INC., 4130 PARKLAKE AVENUE, SUITE 400, RALEIGH, NC, 27612.
Over the last 10 years, insiders at PRA Health Sciences Inc have traded over $5,843,308,181 worth of PRA Health Sciences Inc stock. The most active insiders traders include Fund Holdings L.P.Kkr Fund ..., Fund Holdings L.P.Kkr Fund ..., and Pra Investors L.P.Kkr Pra I.... On average, PRA Health Sciences Inc executives and independent directors trade stock every 39 days with the average trade being worth of $280,602,577. The most recent stock trade was executed by Christopher L Gaenzle on 17 June 2021, trading 27,497 units of PRAH stock currently worth $2,773,897.
PRA is one of the world's leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA's global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and more than 18,100 employees worldwide. Since 2000, PRA has participated in approximately 4,200 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 100 drugs.
PRA Health Sciences Inc executives and other stock owners filed with the SEC include: